Skip to main content
TALPHERA, INC. logo

TALPHERA, INC. — Investor Relations & Filings

Ticker · TLPH ISIN · US00444T2096 LEI · 549300U8W781S4RBUE66 US Manufacturing
Open in API
Filings indexed 840 across all filing types
Latest filing 2025-09-29 Capital/Financing Update
Country US United States of America
Listing US TLPH

About TALPHERA, INC.

https://talphera.com/

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies designed for use in medically supervised settings. The company aims to support healthcare providers and optimize patient outcomes. A key product in its development pipeline is Niyad, a lyophilized formulation of nafamostat. The company was formerly known as AcelRx Pharmaceuticals Inc.

Recent filings

Filing Released Lang Actions
424B7 Filing
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(7) related to a registration statement for resale of common stock and pre-funded warrants. It details a private placement transaction, use of proceeds, risk factors, and other information typical of a securities offering document. It is not a financial report, earnings release, or management discussion. It is a capital markets document related to financing activities and share registration for resale by selling stockholders. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication notice, but a full prospectus related to capital raising and share registration.
2025-09-29 English
ARS Filing
Annual Report
2025-09-24 English
S-3 Filing
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, dated September 22, 2025, for Talphera, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for resale by selling stockholders. The text includes a preliminary prospectus describing the resale of shares and pre-funded warrants by selling stockholders, details of the private placement, use of proceeds, risk factors, and other related information. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities registration and offering. Therefore, the document fits the category of Capital/Financing Update (CAP).
2025-09-22 English
SCHEDULE 13G Filing
Major Shareholding Notification
2025-09-16 English
D Filing
Regulatory Filings
2025-09-15 English
SCHEDULE 13G Filing
Major Shareholding Notification
2025-09-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.